Atopic Dermatitis - Pipeline Review, H2 2019

Atopic Dermatitis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H2 2019, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 12, 47, 25, 3, 57, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 6 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Atopic Dermatitis (Atopic Eczema) - Overview
Atopic Dermatitis (Atopic Eczema) - Therapeutics Development
Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment
Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development
Atopic Dermatitis (Atopic Eczema) - Drug Profiles
Atopic Dermatitis (Atopic Eczema) - Dormant Projects
Atopic Dermatitis (Atopic Eczema) - Discontinued Products
Atopic Dermatitis (Atopic Eczema) - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 10: Number of Products under Development by Universities/Institutes, H2 2019
Table 11: Products under Development by Companies, H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 14: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 15: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 16: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 17: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 18: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 19: Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Table 20: Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Table 21: Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Table 22: Products under Development by Universities/Institutes, H2 2019
Table 23: Number of Products by Stage and Target, H2 2019
Table 24: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 25: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 26: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Table 27: Number of Products by Stage and Mechanism of Action, H2 2019
Table 28: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 29: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 30: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Table 31: Number of Products by Stage and Route of Administration, H2 2019
Table 32: Number of Products by Stage and Molecule Type, H2 2019
Table 33: Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, H2 2019
Table 34: Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, H2 2019
Table 35: Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, H2 2019
Table 36: Atopic Dermatitis (Atopic Eczema) - Pipeline by Aclaris Therapeutics Inc, H2 2019
Table 37: Atopic Dermatitis (Atopic Eczema) - Pipeline by Afecta Pharmaceuticals Inc, H2 2019
Table 38: Atopic Dermatitis (Atopic Eczema) - Pipeline by Akaal Pharma Pty Ltd, H2 2019
Table 39: Atopic Dermatitis (Atopic Eczema) - Pipeline by Allergan Plc, H2 2019
Table 40: Atopic Dermatitis (Atopic Eczema) - Pipeline by Almirall SA, H2 2019
Table 41: Atopic Dermatitis (Atopic Eczema) - Pipeline by Amgen Inc, H2 2019
Table 42: Atopic Dermatitis (Atopic Eczema) - Pipeline by Amorepacific Corp, H2 2019
Table 43: Atopic Dermatitis (Atopic Eczema) - Pipeline by AOBiome LLC, H2 2019
Table 44: Atopic Dermatitis (Atopic Eczema) - Pipeline by Apimeds Inc, H2 2019
Table 45: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arcutis Inc, H2 2019
Table 46: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arena Pharmaceuticals Inc, H2 2019
Table 47: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arrien Pharmaceuticals LLC, H2 2019
Table 48: Atopic Dermatitis (Atopic Eczema) - Pipeline by Asana BioSciences LLC, H2 2019
Table 49: Atopic Dermatitis (Atopic Eczema) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
Table 50: Atopic Dermatitis (Atopic Eczema) - Pipeline by Astellas Pharma Inc, H2 2019
Table 51: Atopic Dermatitis (Atopic Eczema) - Pipeline by AstraZeneca Plc, H2 2019
Table 52: Atopic Dermatitis (Atopic Eczema) - Pipeline by Atrapos Therapeutics LLC, H2 2019
Table 53: Atopic Dermatitis (Atopic Eczema) - Pipeline by Azitra Inc, H2 2019
Table 54: Atopic Dermatitis (Atopic Eczema) - Pipeline by Bausch Health Companies Inc, H2 2019
Table 55: Atopic Dermatitis (Atopic Eczema) - Pipeline by Biomimetix JV LLC, H2 2019
Table 56: Atopic Dermatitis (Atopic Eczema) - Pipeline by Blueberry Therapeutics Ltd, H2 2019
Table 57: Atopic Dermatitis (Atopic Eczema) - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Table 58: Atopic Dermatitis (Atopic Eczema) - Pipeline by Boston Pharmaceuticals Inc, H2 2019
Table 59: Atopic Dermatitis (Atopic Eczema) - Pipeline by Botanix Pharmaceuticals Ltd, H2 2019
Table 60: Atopic Dermatitis (Atopic Eczema) - Pipeline by Calcico Therapeutics Ltd, H2 2019
List of Figures
Figure 1: Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook